Patents by Inventor Nancy LABBE-GIGUERE

Nancy LABBE-GIGUERE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20240140959
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 30, 2023
    Publication date: May 2, 2024
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James Anthony NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF
    Publication number: 20240043425
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: May 18, 2023
    Publication date: February 8, 2024
    Inventors: Mallesh BUSHABOINA, Xin CHEN, Atwood Kim CHEUNG, Andrew James CULSHAW, Timothy Brian HURLEY, Nancy LABBE-GIGUERE, Wolfgang MILTZ, David ORAIN, Tajesh PATEL, Srinivasan RAJAGOPALAN, Till ROEHN, David Andrew SANDHAM, Gebhard THOMA, Ritesh Bhanudasji TICHKULE, Rudolf WÄLCHLI
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11820778
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: November 21, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
    Patent number: 11708366
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: July 25, 2023
    Assignee: Novartis AG
    Inventors: Mallesh Bushaboina, Xin Chen, Atwood Kim Cheung, Andrew James Culshaw, Timothy Brian Hurley, Nancy Labbe-Giguere, Wolfgang Miltz, David Orain, Tajesh Patel, Srinivasan Rajagopalan, Till Roehn, David Andrew Sandham, Gebhard Thoma, Ritesh Bhanudasji Tichkule, Rudolf Wälchli
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20230212139
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 6, 2023
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11548865
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20220411435
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: August 8, 2022
    Publication date: December 29, 2022
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-azaspiro[3.4]octane derivatives as M4 agonists
    Patent number: 11485742
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: November 1, 2022
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF
    Publication number: 20220048909
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Inventors: Mallesh BUSHABOINA, Xin CHEN, Atwood Kim CHEUNG, Andrew James CULSHAW, Timothy Brian HURLEY, Nancy LABBE-GIGUERE, Wolfgang MILTZ, David ORAIN, Tajesh PATEL, Srinivasan RAJAGOPALAN, Till ROEHN, David Andrew SANDHAM, Gebhard THOMA, Ritesh Bhanudasji TICHKULE, Rudolf WÄLCHLI
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210130365
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 6, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG
  • 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS
    Publication number: 20210107889
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 15, 2021
    Inventors: Amy CALHOUN, Xin CHEN, Kevin Matthew GARDINIER, Edward Charles HALL, Keith JENDZA, Nancy LABBE-GIGUERE, James NEEF, Daniel Steven PALACIOS, Ming QIAN, Michael David SHULTZ, Christopher G. THOMSON, Kate Yaping WANG, Fan YANG